Novel use of acitretin for posttransplant Grover’s disease and cutaneous graft versus host disease

• Neha Gupta, MPH,
• Cesar A. Virgen, MD, PhD,
• Amrita Goyal, MD,
• Andrew A. Lane, MD, PhD,
• Joseph H. Antin, MD,
• Sherrie J. Divito, MD, PhD,
• Cecilia Larocca, MD

Affiliations

Neha Gupta, MPH

Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Case Western Reserve University School of Medicine, Cleveland, Ohio

Cesar A. Virgen, MD, PhD

Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts

Amrita Goyal, MD

Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts

Andrew A. Lane, MD, PhD

Harvard Medical School, Boston, Massachusetts; Blastic Plasmacytoid Dendritic Cell Neoplasm Center, Dana-Farber Cancer Institute, Boston, Massachusetts

Joseph H. Antin, MD

Harvard Medical School, Boston, Massachusetts; Department of Medical Oncology Stem Cell Transplantation Program, Dana-Farber Cancer Institute, Boston, Massachusetts

Sherrie J. Divito, MD, PhD

Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts

Cecilia Larocca, MD

Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Correspondence to: Cecilia Larocca, MD, Assistant Professor of Dermatology, Harvard Medical School Department of Dermatology, Brigham and Women’s Hospital, 221 Longwood Ave, Boston, MA 02115.